GlassScriptPhysician profile
Alexandra Espejo
NPI 1457425381
$2,729.00
in general payments reported to CMS, 2019-2025
19 companies · $530 in 2025
The $530 reported for 2025 was more than what 78% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $341 · 2021: $361 · 2022: $519 · 2023: $474 · 2024: $224 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,227.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $643.90 | 2019-2025 | Precision7, Eysuvis, Tryptyr |
| Johnson & Johnson Vision Care, INC. | $318.79 | 2019-2023 | Acuvue |
| Regeneron Pharmaceuticals, INC. | $267.03 | 2023-2024 | Eylea, Eylea Hd |
| Abbvie INC. | $247.32 | 2022-2024 | |
| Horizon Therapeutics Plc | $240.25 | 2021-2022 | |
| Maculogix, INC. | $129.36 | 2020 | |
| Kala Pharmaceuticals, INC. | $125.00 | 2021 | |
| Bausch & Lomb Americas INC. | $125.00 | 2025 | Miebo, Xiidra |
| Regeneron Healthcare Solutions, INC. | $117.72 | 2020 | |
| Harrow Eye, LLC | $97.65 | 2024-2025 | Vevye, Natacyn, Flarex |
| Johnson & Johnson Surgical Vision, INC. | $74.45 | 2019 | |
| Allergan, INC. | $60.85 | 2019 | |
| Novartis Pharmaceuticals Corporation | $60.04 | 2021 | |
| Coopervision INC. | $58.65 | 2022-2023 | Misight Contact Lens |
| Sun Pharmaceutical Industries INC. | $52.97 | 2021-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Visionix USA, INC | $41.67 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $25.52 | 2024 | Xdemvy |
| Dompe US, INC. | $22.50 | 2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $20.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Espejo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.